Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation

Bin Yangyang; Li Jiequn; Li Qiang; Zhou Zhengjun; Zhou Yi; Chen Guangshun; Qi Haizhi; Si Zhongzhou

doi:10.3969/j.issn.1674-7445.2020.03.011

Volume 11 Issue 3

May 2020

Turn off MathJax

Article Contents

Article Navigation > ORGAN TRANSPLANTATION > 2020 > 11(3): 384-390

Bin Yangyang, Li Jiequn, Li Qiang, et al. Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation[J]. ORGAN TRANSPLANTATION, 2020, 11(3): 384-390. doi: 10.3969/j.issn.1674-7445.2020.03.011

Citation:

PDF( 792 KB)

Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation

doi: 10.3969/j.issn.1674-7445.2020.03.011

Department of General Surgery and Transplantation, Xiangya Second Hospital of Central South University, Changsha 410013, China

More Information

Corresponding author: Si Zhongzhou, Email: sizhongzhou@csu.edu.cn
Received Date: 2020-02-17
Available Online: 2021-01-19
Publish Date: 2020-05-15

Abstract

Abstract

Objective To investigate the efficacy and safety of programmed cell death protein-1 (PD-1) monoclonal antibody on the treatment of malignant tumor after solid organ transplantation (SOT). Methods The relevant literatures in 7 databases were searched. The data on 54 cases of recipients with malignant tumors treated with PD-1 monoclonal antibody after SOT were collected, and the clinical effects and rejection of SOT recipients treated with PD-1 monoclonal antibody were analyzed. Results Total 32 acceptable articles including 54 SOT recipients were incorporated, including 43 males and 11 females aged 14-79 years old. There are 29 renal transplant recipients, 19 liver transplant recipients and 6 heart transplant recipients. The types of PD-1 monoclonal antibody agent used by SOT recipients included pembrolizumab for 28 patients and nivolumab for 26 patients. The overall remission rate, disease progression rate and fatality rate of PD-1 monoclonal antibody for postoperative malignant tumors of SOT recipients were 32% (17/54), 44% (24/54) and 36% (19/54), respectively. After treatment with PD-1 monoclonal antibody for postoperative malignant tumors of SOT recipients, the incidence of rejection was 39% (21/54), indicating no significant correlation between rejection and type of PD-1 monoclonal antibody (P > 0.05). Conclusions PD-1 monoclonal antibody can effectively treat postoperative malignant tumors of SOT recipients, and may induce rejection during the treatment. But rejection is not the most common cause for death of recipients.
- Tumor immunity,
- Programmed cell death protein-1(PD-1),
- Solid organ transplantation,
- Malignant tumor,
- Literature analysis,
- Immune checkpoint inhibitor

FullText(HTML)

References(44)

References

[1]	YANG Y. Cancer immunotherapy: harnessing the immune system to battle cancer[J]. J Clin Invest, 2015, 125(9):3335-3337. DOI: 10.1172/JCI83871.
[2]	GUNTURI A, MCDERMOTT DF. Potential of new therapies like anti-PD1 in kidney cancer[J]. Curr Treat Options Oncol, 2014, 15(1):137-146. DOI: 10.1007/s11864-013-0268-y.
[3]	BACHY E, COIFFIER B. Anti-PD1 antibody: a new approach to treatment of lymphomas[J]. Lancet Oncol, 2014, 15(1):7-8. DOI: 10.1016/S1470-2045(13)70587-4.
[4]	全诗翠, 胡佳, 刘畅, 等.免疫靶点PD-1/PD-L1的研究现状与应用进展[J].实用医学杂志, 2018, 34(14):2283-2286. DOI: 10.3969/j.issn.1006-5725.2018.14.001. QUAN SC, HU J, LIU C, et al. Research status and application progress of immunotarget PD-1/PD-L1[J]. J Pract Med, 2018, 34(14):2283-2286. DOI:10.3969/j.issn.1006-5725. 2018.14.001.
[5]	MAGGIORE U, PASCUAL J. The bad and the good news on cancer immunotherapy: implications for organ transplant recipients[J]. Adv Chronic Kidney Dis, 2016, 23(5):312-316. DOI: 10.1053/j.ackd.2016.08.002.
[6]	EISENHAUER EA, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) [J]. Eur J Cancer, 2009, 45(2):228-247. DOI: 10.1016/j.ejca.2008.10.026.
[7]	汪国营, 唐晖, 张英才, 等.程序性死亡受体(PD)-1单克隆抗体治疗肝癌肝移植术后复发诱发急性免疫性肝炎:附1例报告[J].器官移植, 2016, 7(1):44-47.DOI: 10.3969/j.issn.1674-7445.2016.01.008. WANG GY, TANG H, ZHANG YC, et al. Programmed death receptor(PD)-1 monoclonal antibody-induced acute immune hepatitis in the treatment of recurrent hepatocellular carcinoma after liver transplantation:a case report[J]. Organ Transplant, 2016, 7(1):44-47. DOI: 10.3969/j.issn.1674-7445.2016.01.008.
[8]	VARKARIS A, LEWIS DW, NUGENT FW. Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma[J]. Am J Gastroenterol, 2017, 112(12):1895-1896. DOI: 10.1038/ajg.2017.387.
[9]	RAMMOHAN A, REDDY MS, FAROUK M, et al. Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: the silver bullet? [J]. Hepatology, 2018, 67(3):1166-1168. DOI: 10.1002/hep.29575.
[10]	SCHVARTSMAN G, PEREZ K, SOOD G, et al. Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma[J]. Ann Intern Med, 2017, 167(5):361-362. DOI: 10.7326/L17-0187.
[11]	TIO M, RAI R, EZEOKE OM, et al. Anti-PD-1/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B/C infection[J]. Eur J Cancer, 2018, 104:137-144. DOI: 10.1016/j.ejca.2018.09.017.
[12]	ABDEL-WAHAB N, SAFA H, ABUDAYYEH A, et al. Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature[J]. J Immunother Cancer, 2019, 7(1):106. DOI: 10.1186/s40425-019-0585-1.
[13]	KUO JC, LILLY LB, HOGG D. Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review[J]. Melanoma Res, 2018, 28(1):61-64. DOI: 10.1097/CMR.0000000000000410.
[14]	DELEON TT, SALOMAO MA, AQEL BA, et al. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience[J]. J Gastrointest Oncol, 2018, 9(6):1054-1062. DOI: 10.21037/jgo.2018.07.05.
[15]	GASSMANN D, WEILER S, MERTENS JC, et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research[J]. Transplant Direct, 2018, 4(8):e376. DOI: 10.1097/TXD.0000000000000814.
[16]	FRIEND BD, VENICK RS, MCDIARMID SV, et al. Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma[J]. Pediatr Blood Cancer, 2017, 64(12). DOI: 10.1002/pbc.26682.
[17]	DE TONI EN, GERBES AL. Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient[J]. Gastroenterology, 2017, 152(6):1631-1633. DOI: 10.1053/j.gastro.2017.01.063.
[18]	BIONDANI P, DE MARTIN E, SAMUEL D. Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient[J]. Ann Oncol, 2018, 29(1):286-287. DOI: 10.1093/annonc/mdx548.
[19]	QIN R, SALAMA AK. Report of ipilimumab in a heart transplant patient with metastatic melanoma on tacrolimus[J]. Melanoma Manag, 2015, 2(4):311-314. DOI: 10.2217/mmt.15.27.
[20]	GRANT MJ, DEVITO N, SALAMA AKS. Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations[J]. Melanoma Manag, 2018, 5(4):MMT10. DOI: 10.2217/mmt-2018-0004.
[21]	OWONIKOKO TK, KUMAR M, YANG S, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report[J]. Cancer Immunol Immunother, 2017, 66(1):45-50. DOI: 10.1007/s00262-016-1918-2.
[22]	KITTAI AS, OLDHAM H, CETNAR J, et al. Immune checkpoint inhibitors in organ transplant patients[J]. J Immunother, 2017, 40(7):277-281. DOI: 10.1097/CJI.0000000000000180.
[23]	WU CK, JUANG GD, LAI HC. Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration[J]. Ann Oncol, 2017, 28(11):2895-2896. DOI: 10.1093/annonc/mdx409.
[24]	WINKLER JK, GUTZMER R, BENDER C, et al. Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature[J]. J Immunother, 2017, 40(9):341-344. DOI: 10.1097/CJI.0000000000000188.
[25]	SADAAT M, JANG S. Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy[J]. J Oncol Pract, 2018, 14(3):198-199. DOI: 10.1200/JOP.2017.027326.
[26]	LIPSON EJ, BAGNASCO SM, MOORE J JR, et al. Tumor regression and allograft rejection after administration of anti-PD-1[J]. N Engl J Med, 2016, 374(9):896-898. DOI: 10.1056/NEJMc1509268.
[27]	KWATRA V, KARANTH NV, PRIYADARSHANA K, et al. Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report[J]. J Med Case Rep, 2017, 11(1):73. DOI: 10.1186/s13256-017-1229-z.
[28]	ALHAMAD T, VENKATACHALAM K, LINETTE GP, et al. Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection[J]. Am J Transplant, 2016, 16(4):1332-1333. DOI: 10.1111/ajt.13711.
[29]	TAMAIN M, GARROUSTE C, AGUILERA D, et al. Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma[J]. Transpl Int, 2016, 29(11):1247-1248. DOI: 10.1111/tri.12834.
[30]	SPAIN L, HIGGINS R, GOPALAKRISHNAN K, et al. Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma[J]. Ann Oncol, 2016, 27(6):1135-1137. DOI: 10.1093/annonc/mdw130.
[31]	SINGH P, VISGER VON J, PROSEK J, et al. Preserved renal allograft function and successful treatment of metastatic merkel cell cancer post nivolumab therapy[J]. Transplantation, 2019, 103(2):e52-e53. DOI: 10.1097/TP.0000000000002502.
[32]	ONG M, IBRAHIM AM, BOURASSA-BLANCHETTE S, et al. Antitumor activity of nivolumab on hemodialysis after renal allograft rejection[J]. J Immunother Cancer, 2016, 4:64. doi: 10.1186/s40425-016-0171-8
[33]	MILLER DM, FAULKNER-JONES BE, STONE JR, et al. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade[J]. JAAD Case Rep, 2017, 3(5):412-415. DOI: 10.1016/j.jdcr.2017.06.005.
[34]	HERZ S, HÖFER T, PAPAPANAGIOTOU M, et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient[J]. Eur J Cancer, 2016, 67:66-72. DOI: 10.1016/j.ejca.2016.07.026.
[35]	GOLDMAN JW, ABDALLA B, MENDENHALL MA, et al. PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - case report[J]. BMC Nephrol, 2018, 19(1):210. DOI: 10.1186/s12882-018-1003-5.
[36]	DELTOMBE C, GARANDEAU C, RENAUDIN K, et al. Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1 therapy in a kidney transplanted patient[J]. Transplantation, 2017, 101(9):e291. DOI: 10.1097/TP.0000000000001861.
[37]	BOILS CL, ALJADIR DN, CANTAFIO AW. Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy[J]. Am J Transplant, 2016, 16(8):2496-2497. DOI: 10.1111/ajt.13786.
[38]	BARNETT R, BARTA VS, JHAVERI KD. Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab[J]. N Engl J Med, 2017, 376(2):191-192. DOI: 10.1056/NEJMc1614298.
[39]	SHI XL, MANCHAM S, HANSEN BE, et al. Counter-regulation of rejection activity against human liver grafts by donor PD-L1 and recipient PD-1 interaction[J]. J Hepatol, 2016, 64(6):1274-1282. DOI: 10.1016/j.jhep.2016.02.034.
[40]	TANAKA K, ALBIN MJ, YUAN X, et al. PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection[J]. J Immunol, 2007, 179(8):5204-5210. doi: 10.4049/jimmunol.179.8.5204
[41]	THANGAVELU G, MURPHY KM, YAGITA H, et al. The role of co-inhibitory signals in spontaneous tolerance of weakly mismatched transplants[J]. Immunobiology, 2011, 216(8):918-924. DOI: 10.1016/j.imbio.2011.01.007.
[42]	AGUIRRE LE, GUZMAN ME, LOPES G, et al. Immune checkpoint inhibitors and the risk of allograft rejection: a comprehensive analysis on an emerging issue[J]. Oncologist, 2019, 24(3):394-401. DOI: 10.1634/theoncologist.2018-0195.
[43]	HODI FS, CHIARION-SILENI V, GONZALEZ R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial[J]. Lancet Oncol, 2018, 19(11):1480-1492. DOI: 10.1016/S1470-2045(18)30700-9.
[44]	SCHACHTER J, RIBAS A, LONG GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) [J]. Lancet, 2017, 390(10105):1853-1862. DOI: 10.1016/S0140-6736(17)31601-X.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (295) PDF downloads(34)

Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation

doi: 10.3969/j.issn.1674-7445.2020.03.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Systematic evaluation on PD-1 monoclonal antibody in the treatment of malignant tumor after solid organ transplantation

doi: 10.3969/j.issn.1674-7445.2020.03.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Export File

Citation

Format

Content